ArticlePituitary2019
Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers.
Article in Pituitary, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Characterization of the secretory profile of gonadotroph pituitary tumors.Journal of endocrinological investigation · 2026Article
- Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.Journal of neuro-oncology · 2026Article
- Histogram analysis based on contrast-enhanced T1-weighted imaging in pituitary macroadenomas: relation to histological subtype and expression.Quantitative imaging in medicine and surgery · 2026Article
- The Roles of PD-L1, Ki-67, P53, and Cyclin D1 in PitNETs: Diagnostic and Prognostic Implications in a Series of 74 Patients.International journal of molecular sciences · 2025Article
- Clinical integration and application of the 2022 WHO pituitary tumor classification.Neuro-oncology advances · 2025Article
- Cell Lineage-Specific Differences in Clinical Behavior of Non-Functioning Pituitary Adenomas.The Journal of clinical endocrinology and metabolism · 2025Article
- Associations ofFrontiers in endocrinology · 2025Article
- The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025Review
- Is radiomics a useful addition to magnetic resonance imaging in the preoperative classification of PitNETs?Acta neurochirurgica · 2024Article
- Pathological characteristics of reoperated regrowing clinically nonfunctioning pituitary tumor cases in comparison with initial surgical cases.Frontiers in endocrinology · 2024Article
- The current state of MRI-based radiomics in pituitary adenoma: promising but challenging.Frontiers in endocrinology · 2024Review
- Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.Endocrinology and metabolism (Seoul, Korea) · 2023Review
- Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.Cancers · 2023Review
- Immunohistochemical and ultrastructural review of six cases previously diagnosed as null cell PitNETs.Brain tumor pathology · 2023Article
- Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future.Endocrine pathology · 2023Review
- The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors-An Overview of the Latest Classifications.International journal of molecular sciences · 2023Review
- Recent advances in understanding and managing pituitary adenomas.Faculty reviews · 2023Review
- The evolution in pituitary tumour classification: a clinical perspective.Endocrine oncology (Bristol, England) · 2023Review
- Article
- Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors.Cell research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe 2017 World Health Organization classification of pituitary tumors redefined pituitary null cell adenomas (NCAs) by restricting this diagnostic category to pituitary tumors that are negative for pituitary transcription factors and adenohypophyseal hormones. The clinical behavior of this redefined entity has not been widely studied, and this is a major shortcoming of the classification. This study evaluated the imaging and clinical features of NCAs from two pituitary centers and compared them with those of gonadotroph adenomas (GAs).
methodsImaging, pathologic, and clinical characteristics of NCAs and GAs were retrospectively reviewed. Tumor immunohistochemistry was performed to confirm absence of adenohypophyseal hormones and pituitary transcription factor expression.
resultsThirty-one NCAs were compared with 38 GAs. NCAs were more likely to invade the cavernous sinus (15/31 [48%] vs. 5/38 [13%], P = .003) and had a higher proliferative index (i.e., MIB-1 > 3%, 11/31 [35%] vs. 5/38 [13%], P = .04). Gross total resection was less likely in the NCA group (19/31 [61%] vs. 33/38 [87], P = .02). Progression-free survival was worse in the NCA cohort (5-year progression-free survival, 0.70 vs. 1.00; P = .011, by log-rank test).
conclusionsCompared with GAs, NCAs are more invasive at the time of presentation and have a more aggressive clinical course. This study provides evidence that NCAs represent a distinct clinicopathologic entity with behavior that differs adversely from that of GAs. This may inform clinical decision-making, including frequency of postoperative tumor surveillance and timing of adjunctive treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.